[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:niemann-pick-disease-type-c":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":47,"states":48},"Niemann-Pick Disease, Type C",6,5,[8,16,22,28,34,40],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07082725","A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)",[12],"Phase 3","RECRUITING","2026-08-26T02:18:11.042248Z","2026-05-05T02:43:27.827875Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05163288","A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C",[12],"2026-08-26T02:15:51.395565Z","2026-04-29T02:57:57.164919Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT07054515","A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis",[12],"2026-08-26T02:18:57.189473Z","2026-05-05T02:43:29.464579Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT00344331","Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C",[],"2026-08-26T02:18:25.327036Z","2026-07-05T05:32:16.769123Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":38,"content_modified":39},"NCT05588167","Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C",[],"2026-08-26T02:17:30.961790Z","2026-05-13T02:55:06.363520Z",{"nct_id":41,"title":42,"phases":43,"status":44,"updated_at":45,"content_modified":46},"NCT05368038","ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program",[],"ENROLLING_BY_INVITATION","2026-08-26T02:18:52.966503Z","2026-06-16T05:54:08.030731Z",[],[49],{"state":50,"count":51,"slug":52},"Minnesota",3,"minnesota"]